AlphaCrest Capital Management LLC - HALOZYME THERAPEUTICS INC ownership

HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 425 filers reported holding HALOZYME THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 0.31 and the average weighting 0.2%.

Quarter-by-quarter ownership
AlphaCrest Capital Management LLC ownership history of HALOZYME THERAPEUTICS INC
ValueSharesWeighting
Q3 2022$434,000
-77.4%
10,972
-74.9%
0.03%
-72.0%
Q2 2022$1,924,000
+92.8%
43,731
+74.8%
0.09%
+66.1%
Q1 2022$998,000
-36.4%
25,017
-35.8%
0.06%
-3.4%
Q4 2021$1,568,000
-26.7%
38,996
-25.8%
0.06%
-47.7%
Q3 2021$2,138,000
+87.1%
52,545
+108.7%
0.11%
+126.5%
Q2 2021$1,143,000
+35.7%
25,177
+24.7%
0.05%
+4.3%
Q1 2021$842,000
+28.2%
20,193
+31.2%
0.05%
-14.5%
Q4 2020$657,000
+105.3%
15,392
+26.2%
0.06%
+57.1%
Q3 2020$320,000
-21.0%
12,195
-53.3%
0.04%
+40.0%
Q3 2019$405,000
+27.4%
26,100
+41.1%
0.02%
-10.7%
Q2 2019$318,000
-62.4%
18,500
-64.8%
0.03%
-78.1%
Q1 2019$845,00052,5000.13%
Other shareholders
HALOZYME THERAPEUTICS INC shareholders Q4 2022
NameSharesValueWeighting ↓
Third Security, LLC 19,829,337$266,308,00010.60%
BB BIOTECH AG 6,929,832$93,068,0002.95%
SECTORAL ASSET MANAGEMENT INC 2,671,051$35,872,0001.64%
Sterling Global Strategies LLC 22,000$295,0001.63%
Lombard Odier Asset Management (USA) Corp 1,061,547$14,257,0001.24%
PYRRHO CAPITAL MANAGEMENT, LP 90,000$1,209,0001.04%
IRIDIAN ASSET MANAGEMENT LLC/CT 8,184,003$109,911,0000.93%
Bellevue Asset Management AG 246,000$3,304,0000.54%
Convergence Investment Partners, LLC 251,748$3,381,0000.39%
Rhenman & Partners Asset Management AB 172,000$2,310,0000.37%
View complete list of HALOZYME THERAPEUTICS INC shareholders